[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 66 pages | ID: MC36B12989A2EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 3, 3 and 2 respectively.

Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Oncology and Women's Health which include indications Obesity, Anorexia Nervosa, Cachexia, Cancer Anorexia-Cachexia Syndrome, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, IgA Nephropathy (Berger's Disease), Metabolic Syndrome, Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome) and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
  • The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocortin Receptor 4 (MC4R)+ targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope
Introduction
Global Markets Direct Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
Endevica Bio
LG Chem Ltd
Mallinckrodt Plc
Palatin Technologies Inc
Pfizer Inc
Rhythm Pharmaceuticals Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
corticotropin - Drug Profile
Product Description
Mechanism Of Action
History of Events
LB-54640 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-07258669 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-9610 - Drug Profile
Product Description
Mechanism Of Action
setmelanotide - Drug Profile
Product Description
Mechanism Of Action
History of Events
setmelanotide hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
TCMCB-07 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Jul 26, 2022: Palatin announces preliminary fourth quarter Vyleesi net product revenue increased 225% over prior quarter
Jul 22, 2022: Rhythm Pharmaceuticals receives positive CHMP opinion for IMCIVREE(setmelanotide) for the treatment of obesity and control of hunger in patients with Bardet-Biedl Syndrome
Jul 20, 2022: Rhythm pharmaceuticals announces early access authorization for setmelanotide for use in patients with Bardet-Biedl syndrome in France
Jul 20, 2022: Rhythm Pharmaceuticals announces early access authorization for setmelanotide for use in patients with Bardet-Biedl Syndrome in France
Jul 18, 2022: NICE recommends Rhythm’s IMCIVREE (setmelanotide) for treating obesity and controlling hunger caused by POMC or LEPR Deficiency
Jul 13, 2022: Endevica Bio doses first patient in phase 1 clinical trial of TCMCB07 for the treatment of cachexia
Jul 12, 2022: Rhythm Pharmaceuticals announces positive interim results from phase 2 clinical trial evaluating setmelanotide in hypothalamic obesity
Jun 28, 2022: Endevica reports the U.S. FDA accepted its Investigational New Drug (IND) Application for TCMCB07, a Melanocortin-4 Antagonist Peptide
Jun 22, 2022: Rhythm Pharmaceuticals launches IMCIVREE (setmelanotide) in Germany for the treatment of obesity and control of hunger associated with POMC or LEPR deficiency
Jun 22, 2022: Rhythm Pharmaceuticals announces that European Commission authorized variation for IMCIVREE (setmelanotide) to allow for dosing in patients with POMC or LEPR deficiency with renal impairment
Jun 16, 2022: LG Chem’s new drug for obesity receives additional orphan drug designation by the US FDA
Jun 16, 2022: Rhythm Pharmaceuticals announces FDA approval of IMCIVREE (setmelanotide) for use in patients with Bardet-Biedl Syndrome
Jun 13, 2022: Rhythm Pharmaceuticals presents new data from long-term extension trial evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR deficiency obesity at ENDO 2022
May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference
May 02, 2022: Rhythm Pharmaceuticals presents new data from phase 3 trial evaluating setmelanotide in patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Endevica Bio, 2022
Pipeline by LG Chem Ltd, 2022
Pipeline by Mallinckrodt Plc, 2022
Pipeline by Palatin Technologies Inc, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Rhythm Pharmaceuticals Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications